
Scientists have identified an enzyme that promotes fat synthesis and demonstrated that inhibiting it stops weight gain and reduces cholesterol levels in mice.
Obesity has become one of the most prevalent global health problems and is a leading cause of avoidable illness and premature mortality. It greatly raises the likelihood of associated conditions such as cardiovascular disease and metabolic dysfunction–associated steatotic liver disease (MASLD). These patterns have intensified as contemporary lifestyles promote energy-dense diets and lower levels of physical activity.
The new study focuses on nitric oxide, a small gaseous molecule that plays a crucial role in regulating numerous biological functions.
Nitric oxide affects cellular behavior by attaching to specific proteins and altering how they work. When this signaling pathway is disrupted—whether by excessive or insufficient nitric oxide modification of key proteins—normal metabolic regulation can fail, increasing the risk of disease.
In a study reported in Science Signaling, researchers from University Hospitals and Case Western Reserve University identified a previously unrecognized enzyme called SCoR2. This enzyme strips nitric oxide from proteins that regulate fat storage and production in the body. By removing nitric oxide from these targets, SCoR2 activates fat synthesis, revealing its pivotal role in the body’s capacity to produce fat and highlighting its potential as a target for new treatments.
Shutting Down Fat Synthesis
The team next shut down SCoR2 using genetic approaches as well as a newly created drug. In mouse studies, blocking this nitric oxide–removing enzyme stopped weight gain and lessened liver injury, while the drug also reduced levels of harmful cholesterol.
“We’ve identified a new category of drug that both blocks weight gain and reduces cholesterol, offering a promising treatment approach for obesity and cardiovascular disease, along with added benefits for the liver,” said study lead author Jonathan Stamler, MD, President and Co-Founder of the Harrington Discovery Institute and a Distinguished University Professor at University Hospitals and Case Western Reserve University.
He further explained that in the liver, nitric oxide suppresses proteins responsible for producing fat and cholesterol, while in adipose tissue it shuts down the genetic program that drives the enzymes involved in fat creation.
A Novel Approach to Tackling Obesity
The next phase of this research will move the drug into clinical trials, expected to take roughly 18 months.
“Our team is eager to continue developing this first-of-its-kind drug to prevent weight gain and reduce cholesterol, while also benefiting liver health,” said Dr. Stamler.
Read the original article on: SciTechDaily
Read more: An injectable Weight-loss Drug can Reduce Leftover Post-Surgery Pounds


